Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.

Lamont EB, Herndon JE 2nd, Weeks JC, Henderson IC, Lilenbaum R, Schilsky RL, Christakis NA.

J Natl Cancer Inst. 2005 Jul 20;97(14):1080-3.

PMID:
16030306
2.

Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants.

Lamont EB, Herndon JE 2nd, Weeks JC, Henderson IC, Lilenbaum R, Schilsky RL, Christakis NA; Cancer and Leukemia Group B.

Med Care. 2008 Mar;46(3):303-8. doi: 10.1097/MLR.0b013e31815cecc3.

3.

Sensitivity of Medicare claims data for measuring use of standard multiagent chemotherapy regimens.

Lamont EB, Lan L.

Med Care. 2014 Mar;52(3):e15-20. doi: 10.1097/MLR.0b013e31824e342f.

4.

Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis.

Duh MS, Reynolds Weiner J, Lefebvre P, Neary M, Skarin AT.

Curr Med Res Opin. 2008 Apr;24(4):967-74. doi: 10.1185/030079908X280464 . Epub 2008 Feb 15.

PMID:
18282373
5.

Does economics matter when treating advanced non-small cell lung cancer?

Ramsey SD, Kessler LG.

Oncologist. 2002;7(3):179-80. No abstract available.

6.
8.

Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344).

Lamont EB, Herndon JE 2nd, Weeks JC, Henderson IC, Earle CC, Schilsky RL, Christakis NA; Cancer and Leukemia Group B.

J Natl Cancer Inst. 2006 Sep 20;98(18):1335-8. Erratum in: J Natl Cancer Inst. 2008 Jan 2;100(1):70. J Natl Cancer Inst. 2006 Nov 1;98(21):1584.

9.

Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.

Zhu J, Sharma DB, Chen AB, Johnson BE, Weeks JC, Schrag D.

Cancer. 2013 Jun 1;119(11):2048-60. doi: 10.1002/cncr.28022. Epub 2013 Apr 5.

10.

Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.

Brown T, Boland A, Bagust A, Oyee J, Hockenhull J, Dundar Y, Dickson R, Ramani VS, Proudlove C.

Health Technol Assess. 2010 Oct;14(Suppl. 2):71-9. doi: 10.3310/hta14suppl2/10. Review.

PMID:
21047494
12.

Evaluation of paclitaxel and carboplatin versus combination chemotherapy with fluorouracil, doxorubicin and cyclophosphamide as a neoadjuvant therapy in patients with inoperable breast cancer.

Akhtar MS, Kousar F, Masood M, Fatimi S, Kokab.

J Coll Physicians Surg Pak. 2010 Nov;20(11):748-52. doi: 04.2010/JCPSP.748752.

PMID:
21078249
13.

Adjuvant chemotherapy for early-stage breast cancer: the tAnGo trial.

Poole C.

Oncology (Williston Park). 2004 Dec;18(14 Suppl 12):23-6. Review.

14.

A systematic overview of chemotherapy effects in ovarian cancer.

Högberg T, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):340-60. Review.

PMID:
11441940
15.
16.

Hospital-based health care use correlates with incidence of adverse events among elderly Medicare patients treated in adjuvant chemotherapy trials (Alliance 70802).

Lamont EB, Yu M, He Y, Saltz L, Muss H, Zaslavsky AM; Alliance for Clinical Trials in Oncology.

J Geriatr Oncol. 2014 Jul;5(3):230-7. doi: 10.1016/j.jgo.2014.02.001. Epub 2014 Mar 1.

17.

Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65 years of age with stage III non-small cell lung cancer.

Ezer N, Smith CB, Galsky MD, Mhango G, Gu F, Gomez J, Strauss GM, Wisnivesky J.

Radiother Oncol. 2014 Aug;112(2):272-8. doi: 10.1016/j.radonc.2014.07.014. Epub 2014 Aug 20.

PMID:
25150635
18.

Optimal chemotherapy treatment for women with recurrent ovarian cancer.

Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P.

Curr Oncol. 2007 Oct;14(5):195-208.

19.

Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer.

Dombernowsky P, Gehl J, Boesgaard M, Jensen TP, Jensen BV.

Semin Oncol. 1996 Feb;23(1 Suppl 1):13-8. Review.

PMID:
8629030
20.

Carboplatin in combination therapy for metastatic breast cancer.

Perez EA.

Oncologist. 2004;9(5):518-27. Review.

Supplemental Content

Support Center